20/20 Biolabs, Inc. (AIDX): Entry into a Material Definitive Agreement
20/20 Biolabs, Inc. (AIDX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ea029890701ex10-1.htm STANDSTILL AGREEMENT, DATED JULY 16, 2026, BETWEEN STREETERVILLE CAPITAL, LLC AND 20/20 BIOLABS, INC Exhibit 10.1 STANDSTILL AGREEMENT This Standstill Agreement (this “ Agreement ”) is entered into as of July 16, 2026 (the “ Effective Date ”) by an
How this was made
The 30-second read
Why it matters
By restricting Investor from converting Series E into common for 120 days unless the common trades at least 10% above the Nasdaq minimum price, the agreement changes the timing of potential dilution and associated selling pressure. It also explicitly states the Company remains obligated to issue conversion shares upon receipt of a conversion notice, subject to the standstill conditions and termination triggers.
Market read
Traders should model a reduced near-term conversion/dilution overhang for AIDX, with a defined catalyst date risk as the 120-day standstill approaches expiration or if a breach/Event of Default occurs.
What to watch
The standstill terminates immediately upon breach or an Event of Default, so credit/operational risk could quickly reintroduce conversion pressure before the 120-day period ends.
Background
The 8-K reports Item 1.01, entry into a material definitive agreement, specifically a standstill tied to prior issuance of Series E convertible preferred to Streeterville Capital under a Nov 17, 2025 securities purchase agreement.
Ticker impact
AIDX entered a standstill agreement with Streeterville Capital limiting Investor conversion of Series E preferred into common for 120 days unless price clears a 10% threshold.
Near-term downside pressure from conversion overhang may ease, but the stock remains exposed to a step-up in conversion risk after the 120-day standstill ends.
The filing discloses a concrete conversion restriction tied to Nasdaq minimum price and a defined 120-day window, which is directly relevant to dilution timing and risk. However, the agreement’s net impact depends on AIDX’s share price path versus the 10% threshold and whether any breach/event of default occurs.
Market effects
Highlights ongoing financing structures in small-cap biotech, where preferred-to-common conversion terms can drive dilution risk and trading volatility.
Primarily US-listed microcap dynamics tied to Nasdaq minimum price rules.
Limited beyond the issuer and its capital structure.
Counterpoint
If AIDX’s stock trades above the 10% threshold frequently, the standstill may not meaningfully delay conversions, limiting any relief rally.
Key entities
- issuer20/20 Biolabs, Inc.
Company entering the standstill agreement that limits near-term conversion of its Series E convertible preferred into common shares.
- investorStreeterville Capital, LLC
Investor party agreeing to refrain from seeking conversions during the standstill period under specified price conditions.
